🔴 Biovie is trading 7.26% down on October 21, 2026 with no confirmed company-specific catalyst

Biovie is trading 7.26% down at $1.15, with no confirmed company-specific catalyst identified for the October 21 decline.

• On October 20, the company presented Phase 2 Parkinson’s results, reporting improvements in a subgroup with elevated baseline inflammation; this does not establish a cause for the current drop.
• A report notes a Wall Street Zen downgrade to sell, issued Monday—not as a new October 21 action.
• Biotech sector context is positive, so it does not explain Biovie’s decline.